Qiagen N.V. stock (NL0012169213): Deutsche Bank reiterates Buy rating with USD 43 target

Qiagen shares on the NYSE traded slightly higher on 06/02/2026 after Deutsche Bank Research reiterated its Buy rating and USD 43 price target, keeping the Netherlands-based diagnostics group in focus among European healthcare names.

Qiagen N.V. shares were in focus on 06/02/2026 after Deutsche Bank Research reaffirmed its positive stance on the diagnostics specialist, maintaining a Buy rating and a price target of USD 43, according to a dpa-AFX-based note from Frankfurt on that date.Wallstreet-Online as of 06/02/2026 The Netherlands-based company, whose shares trade on the NYSE under the ticker QGEN, thus remains on the radar of major European research houses.

The analyst commentary follows ongoing investor attention on Qiagen after an increase in short interest in May 2026 and ongoing discussions about growth prospects in molecular diagnostics and sample technologies.MarketBeat as of 05/15/2026 On 06/02/2026, the stock changed hands on the NYSE at around the low- to mid-USD 40 range in regular trading, positioning the company within the broader US-listed European healthcare cohort, according to exchange data for that day.Nasdaq as of 06/02/2026

As of: 06/02/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Qiagen
• Sector/industry: Life sciences tools and molecular diagnostics
• Headquarters/country: Venlo, Netherlands
• Core markets: North America, Europe, Asia-Pacific
• Key revenue drivers: Sample preparation kits, molecular diagnostics assays, instrument platforms, and consumables for research and clinical laboratories
• Home exchange/listing venue: NYSE (QGEN)
• Trading currency: USD

Qiagen N.V.: core business model

Qiagen focuses on providing sample-to-insight solutions, combining consumables and instruments that enable laboratories to prepare, analyze, and interpret biological samples for research, clinical diagnostics, and applied testing.

Latest quarterly results for Qiagen N.V. at a glance

For the first quarter of 2026, Qiagen reported net sales of USD 530 million, compared with USD 502 million in the first quarter of 2025, according to its quarterly earnings release published on 04/30/2026.Qiagen investor relations as of 04/30/2026 The company highlighted growth in its non-COVID product portfolio, including molecular diagnostics and life sciences tools, while COVID-related revenues continued to normalize in line with expectations.

On an adjusted basis, earnings per share for Q1 2026 came in at USD 0.53 versus USD 0.47 in the prior-year quarter, reflecting operational leverage and a favorable product mix, as stated in the same report.Qiagen investor relations as of 04/30/2026 Management reiterated its full-year 2026 outlook for net sales growth in the mid-single-digit percentage range and for adjusted EPS to grow at a similar pace, underlining confidence in demand from clinical laboratories and research institutions.

Conclusion

The reiteration of a Buy rating and USD 43 price target by Deutsche Bank Research on 06/02/2026 keeps Qiagen N.V. in focus among NYSE-listed European healthcare names and underlines ongoing interest from major sell-side coverage. The latest Q1 2026 results showed growth in core non-COVID areas and stable profitability, set against a backdrop of rising short interest and broader debates about valuation in life sciences tools. Investors will be watching whether demand for Qiagen's molecular diagnostics and research solutions continues to support the company's full-year guidance and how sentiment evolves as new data points and analyst updates emerge.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.